Market open
INmune Bio/$INMB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About INmune Bio
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Ticker
$INMB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
18
Website
INmune Bio Metrics
BasicAdvanced
$179M
-
-$2.11
1.94
-
Price and volume
Market cap
$179M
Beta
1.94
52-week high
$12.72
52-week low
$4.32
Average daily volume
281K
Financial strength
Current ratio
3.138
Quick ratio
3.093
Long term debt to equity
0.76
Total debt to equity
1.196
Interest coverage (TTM)
-54.04%
Management effectiveness
Return on assets (TTM)
-55.19%
Return on equity (TTM)
-119.83%
Valuation
Price to revenue (TTM)
11,155.492
Price to book
5.43
Price to tangible book (TTM)
11.18
Price to free cash flow (TTM)
-4.675
Growth
Revenue change (TTM)
-90.97%
Earnings per share change (TTM)
26.43%
3-year revenue growth (CAGR)
-57.39%
3-year earnings per share growth (CAGR)
3.91%
What the Analysts think about INmune Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for INmune Bio stock.
INmune Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
INmune Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
INmune Bio News
AllArticlesVideos
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
GlobeNewsWire·2 weeks ago
INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for INmune Bio stock?
INmune Bio (INMB) has a market cap of $179M as of April 28, 2025.
What is the P/E ratio for INmune Bio stock?
The price to earnings (P/E) ratio for INmune Bio (INMB) stock is 0 as of April 28, 2025.
Does INmune Bio stock pay dividends?
No, INmune Bio (INMB) stock does not pay dividends to its shareholders as of April 28, 2025.
When is the next INmune Bio dividend payment date?
INmune Bio (INMB) stock does not pay dividends to its shareholders.
What is the beta indicator for INmune Bio?
INmune Bio (INMB) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.